4.8 Article

Loss of the Birt-Hogg-Dube tumor suppressor results in apoptotic resistance due to aberrant TGFβ-mediated transcription

Journal

ONCOGENE
Volume 30, Issue 22, Pages 2534-2546

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.628

Keywords

BHD; apoptosis; Bim; TGF beta; mTOR

Funding

  1. Myrovlytis Trust (London, UK)
  2. NIH [CA104838]

Ask authors/readers for more resources

Birt-Hogg-Dube (BHD) syndrome is an inherited cancer susceptibility disease characterized by skin and kidney tumors, as well as cystic lung disease, which results from loss-of-function mutations in the BHD gene. BHD is also inactivated in a significant fraction of patients with sporadic renal cancers and idiopathic cystic lung disease, and little is known about its mode of action. To investigate the molecular and cellular basis of BHD tumor suppressor activity, we generated mutant Bhd mice and embryonic stem cell lines. BHD-deficient cells exhibited defects in cell-intrinsic apoptosis that correlated with reduced expression of the BH3-only protein Bim, which was similarly observed in all human and murine BHD-related tumors examined. We further demonstrate that Bim deficiency in Bhd(-/-) cells is not a consequence of elevated mTOR or ERK activity, but results instead from reduced Bim transcription associated with a general loss of TGF beta-mediated transcription and chromatin modifications. In aggregate, this work identifies a specific tumor suppressive mechanism for BHD in regulating TGF beta-dependent transcription and apoptosis, which has implications for the development of targeted therapies. Oncogene (2011) 30, 2534-2546; doi:10.1038/onc.2010.628; published online 24 January 2011

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available